{"status":"ok","message-type":"work","message-version":"1.0.0","message":{"indexed":{"date-parts":[[2026,10,28]],"date-time":"2026-10-28T00:43:12Z","timestamp":1793148192838,"version":"4.5.0"},"reference-count":19,"publisher":"Public Library of Science (PLoS)","issue":"10","license":[{"start":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T00:00:00Z","timestamp":1729036800000},"content-version":"vor","delay-in-days":0,"URL":"http:\/\/creativecommons.org\/licenses\/by\/4.0\/"}],"content-domain":{"domain":["www.plosone.org"],"crossmark-restriction":false},"short-container-title":["PLoS ONE"],"abstract":"<jats:p>Corticosteroids can reduce the mortality rate among patients with severe COVID-19 pneumonia. However, opportunistic infections such as Mycobacterium tuberculosis are of concern, especially among those on high doses of corticosteroids. It is unknown whether the risk of developing subsequent TB infection is high or not among COVID-19 patients on high doses of corticosteroids. Hence, this study was conducted to address this gap of knowledge. We conducted a retrospective, cross-sectional study at the King Chulalongkorn Memorial Hospital from October 12, 2022 to June 30, 2023. Two hundred forty-three participants with documented COVID-19 diagnosis on high dose corticosteroids were enrolled into the study. Baseline characteristics and risk factors of developing TB were collected. The prevalence of TB was significantly different among participants with chronic kidney disease (CKD) stages 2\u20134 and chronic lung diseases. The incidence of TB post 1-year diagnosis of COVID-19 was 4 out of 243 patients (1.6%) or 1,646 cases per 100,000 person-year. The mortality rate among subsequent TB group was significantly much higher than the non-TB group (50% vs 0.4%; p-value = 0.001). COVID-19 participants on high doses of corticosteroids also were co-infected with other infections such as bacteria (37.1%), fungi (5.3%), and <jats:italic>Pneumocystis jirovecii<\/jats:italic> (PJP) (1.2%). We found that the incidence of TB in participants with COVID-19 on high doses of corticosteroids was 11 times higher than the general population. Therefore, we recommend screening for latent TB among these patients to prevent\/early diagnose TB disease.<\/jats:p>","DOI":"10.1371\/journal.pone.0309392","type":"journal-article","created":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:30:48Z","timestamp":1729099848000},"page":"e0309392","update-policy":"https:\/\/doi.org\/10.1371\/journal.pone.corrections_policy","source":"Crossref","is-referenced-by-count":4,"title":["The effect of corticosteroids in developing active pulmonary tuberculosis among patients with COVID-19"],"prefix":"10.1371","volume":"19","author":[{"given":"Thanas","family":"Praphakornmano","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-9507-6339","authenticated-orcid":true,"given":"Pattama","family":"Torvorapanit","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0003-3315-6020","authenticated-orcid":true,"given":"Noppachai","family":"Siranart","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0001-6067-3707","authenticated-orcid":true,"given":"Pirapon June","family":"Ohata","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]},{"ORCID":"https:\/\/orcid.org\/0000-0002-5199-7440","authenticated-orcid":true,"given":"Gompol","family":"Suwanpimolkul","sequence":"additional","affiliation":[],"role":[{"vocabulary":"crossref","role":"author"}]}],"member":"340","published-online":{"date-parts":[[2024,10,16]]},"reference":[{"key":"pone.0309392.ref001","unstructured":"World Health Organization Global Tuberculosis Report 2021: World Health Organization [Available from: https:\/\/apps.who.int\/iris\/rest\/bitstreams\/1379788\/retrieve."},{"key":"pone.0309392.ref002","unstructured":"COVID-19 Coronavirus Pandemic Reported Cases and Deaths: WORLDOMETER; [Available from: https:\/\/www.worldometers.info\/coronavirus\/."},{"issue":"12","key":"pone.0309392.ref003","doi-asserted-by":"crossref","first-page":"549","DOI":"10.1089\/jir.2020.0210","article-title":"Role of Host Immune and Inflammatory Responses in COVID-19 Cases with Underlying Primary Immunodeficiency: A Review","volume":"40","author":"BM Liu","year":"2020","journal-title":"J Interferon Cytokine Res"},{"key":"pone.0309392.ref004","doi-asserted-by":"crossref","first-page":"155478","DOI":"10.1016\/j.cyto.2021.155478","article-title":"Clinical significance of measuring serum cytokine levels as inflammatory biomarkers in adult and pediatric COVID-19 cases: A review.","volume":"142","author":"BM Liu","year":"2021","journal-title":"Cytokine"},{"issue":"11","key":"pone.0309392.ref005","doi-asserted-by":"crossref","first-page":"2866","DOI":"10.1002\/jmv.26165","article-title":"Can steroids reverse the severe COVID-19 induced \"cytokine storm\"?","volume":"92","author":"L Kolilekas","year":"2020","journal-title":"J Med Virol"},{"issue":"1","key":"pone.0309392.ref006","doi-asserted-by":"crossref","first-page":"80","DOI":"10.1016\/j.jiph.2022.11.029","article-title":"First case series and literature review of coronavirus disease 2019 (COVID-19) associated pulmonary tuberculosis in Southeast Asia: Challenges and opportunities.","volume":"16","author":"N Siranart","year":"2023","journal-title":"J Infect Public Health"},{"key":"pone.0309392.ref007","first-page":"56","article-title":"Active tuberculosis, sequelae and COVID-19 co-infection: first cohort of 49 cases","author":"M Tadolini","year":"2020","journal-title":"Eur Respir J"},{"issue":"7","key":"pone.0309392.ref008","doi-asserted-by":"crossref","DOI":"10.3390\/ijms22073773","article-title":"Corticosteroids for COVID-19 Therapy: Potential Implications on Tuberculosis.","volume":"22","author":"R Gopalaswamy","year":"2021","journal-title":"Int J Mol Sci"},{"issue":"4","key":"pone.0309392.ref009","doi-asserted-by":"crossref","first-page":"307","DOI":"10.7883\/yoken.JJID.2020.884","article-title":"Increased Secondary Infection in COVID-19 Patients Treated with Steroids in New York City","volume":"74","author":"R Obata","year":"2021","journal-title":"Jpn J Infect Dis"},{"issue":"8","key":"pone.0309392.ref010","doi-asserted-by":"crossref","first-page":"936","DOI":"10.5588\/ijtld.15.0031","article-title":"Risk of incident active tuberculosis and use of corticosteroids","volume":"19","author":"CC Lai","year":"2015","journal-title":"Int J Tuberc Lung Dis"},{"issue":"6","key":"pone.0309392.ref011","doi-asserted-by":"crossref","first-page":"954","DOI":"10.1093\/clinids\/11.6.954","article-title":"Risk of infectious complications in patients taking glucocorticosteroids","volume":"11","author":"AE Stuck","year":"1989","journal-title":"Rev Infect Dis"},{"issue":"4 Pt 2","key":"pone.0309392.ref012","first-page":"S221","article-title":"Targeted tuberculin testing and treatment of latent tuberculosis infection. This official statement of the American Thoracic Society was adopted by the ATS Board of Directors, July 1999. This is a Joint Statement of the American Thoracic Society (ATS) and the Centers for Disease Control and Prevention (CDC). This statement was endorsed by the Council of the Infectious Diseases Society of America. (IDSA), September 1999, and the sections of this statement","volume":"161","year":"2000","journal-title":"Am J Respir Crit Care Med"},{"issue":"1","key":"pone.0309392.ref013","doi-asserted-by":"crossref","first-page":"1","DOI":"10.1186\/s40360-016-0111-8","article-title":"Deflazacort: therapeutic index, relative potency and equivalent doses versus other corticosteroids.","volume":"18","author":"L. Parente","year":"2017","journal-title":"BMC Pharmacol Toxicol"},{"issue":"2","key":"pone.0309392.ref014","first-page":"e10","article-title":"Updates on the risk factors for latent tuberculosis reactivation and their managements","volume":"5","author":"JW Ai","year":"2016","journal-title":"Emerg Microbes Infect"},{"key":"pone.0309392.ref015","doi-asserted-by":"crossref","first-page":"101825","DOI":"10.1016\/j.eclinm.2023.101825","article-title":"COVID-19 pneumonia and the subsequent risk of getting active pulmonary tuberculosis: a population-based dynamic cohort study using national insurance claims databases","volume":"56","author":"P Kumwichar","year":"2023","journal-title":"EClinicalMedicine"},{"key":"pone.0309392.ref016","unstructured":"Tuberculosis profile: Thailand: TBThailand.org; [Available from: https:\/\/www.tbthailand.org\/statustb.html."},{"issue":"10","key":"pone.0309392.ref017","doi-asserted-by":"crossref","first-page":"2016","DOI":"10.3201\/eid2910.230286","article-title":"Characteristics of and Deaths among 333 Persons with Tuberculosis and COVID-19 in Cross-Sectional Sample from 25 Jurisdictions, United States","volume":"29","author":"SA Nabity","year":"2023","journal-title":"Emerg Infect Dis"},{"issue":"12","key":"pone.0309392.ref018","doi-asserted-by":"crossref","first-page":"1482","DOI":"10.1016\/j.jmoldx.2020.10.003","article-title":"Development and Evaluation of a Fully Automated Molecular Assay Targeting the Mitochondrial Small Subunit rRNA Gene for the Detection of Pneumocystis jirovecii in Bronchoalveolar Lavage Fluid Specimens","volume":"22","author":"B Liu","year":"2020","journal-title":"J Mol Diagn"},{"issue":"6","key":"pone.0309392.ref019","doi-asserted-by":"crossref","first-page":"1367","DOI":"10.1093\/cid\/ciz1008","article-title":"Revision and Update of the Consensus Definitions of Invasive Fungal Disease From the European Organization for Research and Treatment of Cancer and the Mycoses Study Group Education and Research Consortium","volume":"71","author":"JP Donnelly","year":"2020","journal-title":"Clin Infect Dis"}],"container-title":["PLOS ONE"],"original-title":[],"language":"en","link":[{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309392","content-type":"unspecified","content-version":"vor","intended-application":"similarity-checking"}],"deposited":{"date-parts":[[2024,10,16]],"date-time":"2024-10-16T17:30:56Z","timestamp":1729099856000},"score":1,"resource":{"primary":{"URL":"https:\/\/dx.plos.org\/10.1371\/journal.pone.0309392"}},"subtitle":[],"editor":[{"given":"Benjamin M.","family":"Liu","sequence":"first","affiliation":[],"role":[{"vocabulary":"crossref","role":"editor"}]}],"short-title":[],"issued":{"date-parts":[[2024,10,16]]},"references-count":19,"journal-issue":{"issue":"10","published-online":{"date-parts":[[2024,10,16]]}},"URL":"https:\/\/doi.org\/10.1371\/journal.pone.0309392","relation":{},"ISSN":["1932-6203"],"issn-type":[{"value":"1932-6203","type":"electronic"}],"subject":[],"published":{"date-parts":[[2024,10,16]]}}}